# POINT Biopharma

Source: https://nuclide.cc/companies/point-biopharma/  
Nuclide record `point-biopharma` (Company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

POINT Biopharma developed radioactive medicines that home in on prostate cancer and neuroendocrine tumours, and built a large manufacturing campus in Indianapolis. Eli Lilly bought the company at the end of 2023.

## Summary

POINT Biopharma Global Inc. (formerly Nasdaq: PNT) was an Indianapolis radiopharmaceutical company with late-stage radioligand therapies: PNT2002, a PSMA-targeted therapy for metastatic castration-resistant prostate cancer after progression on hormonal treatment, and PNT2003, a somatostatin receptor (SSTR)-targeted therapy for gastroenteropancreatic neuroendocrine tumours, both partnered with Lantheus outside certain Asian territories, plus earlier clinical and preclinical programmes. It operated a 180,000 square foot radiopharmaceutical manufacturing campus in Indianapolis and an R&D centre in Toronto. On 2 October 2023 Eli Lilly agreed to acquire POINT through a cash tender offer of USD 12.50 per share, and the merger was completed in late December 2023; the company website now redirects to lilly.com.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Indianapolis, IN
- Type: radiopharma
- Website: https://www.lilly.com/

## Notes

- pointbiopharma.com redirects to lilly.com, recorded as the website. Deal value and pipeline details come from the Lilly press release filed as exhibit 99.4 to POINT's 8-K of 3 October 2023.

## Sources

- Official website: https://www.lilly.com/
- Form 8-K: merger agreement with Eli Lilly: https://www.sec.gov/Archives/edgar/data/1811764/000110465923106146/tm2327397d1_8k.htm
- Lilly press release (8-K exhibit 99.4): https://www.sec.gov/Archives/edgar/data/1811764/000110465923106146/tm2327397d1_ex99-4.htm
- Form 8-K: completion of merger: https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/d594310d8k.htm

## Connected records

- indications: [Neuroendocrine tumours](https://nuclide.cc/indications/neuroendocrine/), [Prostate cancer](https://nuclide.cc/indications/prostate/)
- technologies: [Radioligand therapy (beta emitters)](https://nuclide.cc/technologies/radioligand-therapy/)
- targets: [PSMA](https://nuclide.cc/targets/psma/), [Somatostatin receptor 2](https://nuclide.cc/targets/sstr2/)
- companies: [Eli Lilly (incl. Loxo)](https://nuclide.cc/companies/eli-lilly/)
- drugs: [Lutetium-177 PNT2002](https://nuclide.cc/drugs/lu-177-pnt2002/)
- fronts: [Radioligand therapy](https://nuclide.cc/fronts/f-radioligand-therapy/)

---
JSON: https://nuclide.cc/api/v1/entities/point-biopharma.json